Overview

TAC Versus TC for Adjuvant Breast Cancer

Status:
Unknown status
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
US Oncology Research
Collaborator:
Sanofi
Treatments:
Cyclophosphamide
Docetaxel
Doxorubicin
Liposomal doxorubicin